Associate Professor

Andrew Nash

FAA FTSE

Andrew Nash
Image Description
Following an eight-year academic career at the University of Melbourne, Dr Nash transitioned to industry R&D, commencing at AMRAD in 1996. He has spent 28 years in various research and executive leadership positions and was most recently Chief Scientific Officer and Head of Research at CSL. In this role he provided overarching scientific leadership and was directly responsible for CSL’s global research activity. Throughout his career Dr Nash has championed the translation of Australian biomedical research outcomes into new therapies for unmet medical needs, led multiple projects that have transitioned into clinical programs, and contributed significantly to the development of an Australian workforce and the supporting infrastructure that is prerequisite for a successful Australian-based biopharmaceutical sector. He currently serves as a Director of the Burnet Institute, Brandon Biocatalyst and Denteric.

Fields of research

31 BIOLOGICAL SCIENCES
  • 3105 GENETICS
    • 310507 Genetic Immunology
32 BIOMEDICAL AND CLINICAL SCIENCES
  • 3206 MEDICAL BIOTECHNOLOGY
34 CHEMICAL SCIENCES
  • 3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY
    • 340406 Molecular Medicine

For full list of research codes, please visit the ARC Website .

Expertise type

  • Antibodies
  • Immunology
  • Biotechnology
  • Drug Discovery
  • Cytokines
  • Research Commercialisation
  • Genetic Basis of Disease
  • Autoimmunity
  • Biology
  • Post-research phase biological drug development

Please contact fellowship@science.org.au to request any updates to the data.